Clinical outcome and prognostic factors of patients with early-stage epithelial ovarian cancer
Authors:
Open Access
- 11 November 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (14) , 23862-23870
Abstract
Some subsets of early stage ovarian cancer patients experience more recurrences than others. Studies on prognostics factors gave conflicting results. We investigated consecutive 221 patients with stage I/II ovarian cancer at our institution from 1999 to 2010. Univariate and multivariate analysis of progression free survival (PFS) and overall survival (OS) were performed. After a median follow-up of 79 months, the 5-year/10-year PFS and 5-year/10-year OS were 78% /76% and 90% /87% respectively. Multivariate analysis revealed that stage as the most prominent independent prognostic factor in terms of PFS (stage I vs stage IIA vs stage IIB, Hazard Ratio (HR): 1 vs 4 vs 6.1, P < 0.05) and OS (stage I vs stage II, HR: 1 vs 2.1, P < 0.05). Peritoneal biopsy reduced the risk of recurrence by 29% (95% CI: 0.15-0.58, P < 0.05). Ascites (HR = 2.8, 95% CI: 1.2-6.6, P < 0.05) and not the first-line chemotherapy (HR = 2.6, 95% CI: 1.1-6.5, P < 0.05) contributed to decreased OS. Overall, early-stage ovarian cancer had a favorable outcome, stage was the most powerful prognostic factor.Keywords
This publication has 26 references indexed in Scilit:
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Staging classification for cancer of the ovary, fallopian tube, and peritoneumInternational Journal of Gynecology & Obstetrics, 2013
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective seriesAnnals of Oncology, 2012
- A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group StudyGynecologic Oncology, 2011
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancersGynecologic Oncology, 2008
- Pathogenesis of Ovarian CancerInternational Journal of Gynecological Pathology, 2008
- Adjuvant Chemotherapy for Early-Stage Ovarian Cancer: Review of the LiteratureJournal of Clinical Oncology, 2007
- Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvisBritish Journal of Cancer, 2006
- Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific TreatmentJournal of Clinical Oncology, 2004
- Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)Annals of Oncology, 1995